Gary S. Chuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gary S. Chuang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Mathew M. Avram
Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston
2 shared publicationsArnold Lee
Tufts Medical Center Department of Otolaryngology Boston Massachusetts
1 shared publicationBarbara A. Gilchrest
Boston Medical Center Department of Dermatology
1 shared publication- Brian C. Leach
Dermatologic Surgery Unit, Colorado Springs Dermatology Clinic, Colorado Springs, Colorado 80910, USA
1 shared publication Daniel Finn
1 shared publicationDavid C. Christiani
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston4Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 29 March 2017
- Published by Springer Nature in Environmental Health
- Vol. 16 (1) , 1-7
Occupational exposures and determinants of ultrafine particle concentrations during laser hair removal procedures
Occupational exposures to ultrafine particles in the plume generated during laser hair removal procedures, the most commonly performed light based cosmetic procedure, have not been thoroughly characterized. Acute and chronic exposures to ambient ultrafine particles have been associated with a number of negative respiratory and cardiovascular health effects. Thus, the aim of this study was to measure airborne concentrations of particles in a diameter size range of 10 nm to 1 μm in procedure rooms during laser hair removal procedures. TSI Model 3007 Condensation Particle Counters were used to quantify the particle count concentrations in the waiting and procedure rooms of a dermatology office. Particle concentrations were sampled before, during, and after laser hair removal procedures, and characteristics of each procedure were noted by the performing dermatologist. Twelve procedures were sampled over 4 days. Mean ultrafine particle concentrations in the waiting and procedure rooms were 14,957.4 particles/cm3 and 22,916.8 particles/cm3 (p < 0.0001), respectively. Compared to background ultrafine particle concentrations before the procedure, the mean concentration in the procedure room was 2.89 times greater during the procedure (p = 0.009) and 2.09 times greater after the procedure (p = 0.007). Duration of procedure (p = 0.006), body part (p = 0.013), and the use of pre-laser lotion/type of laser (p = 0.039), were the most important predictors of ultrafine particle concentrations. Use of a smoke evacuator (a recommended form of local exhaust ventilation) positioned at 30.5 cm from the source, as opposed to the recommended 1–2 in., lowered particle concentrations, but was not a statistically significant predictor (p = 0.49). Laser hair removal procedures can generate high exposures to ultrafine particles for dermatologists and other individuals performing laser hair removal, with exposure varying based on multiple determinants.
- 29 March 2017
- Published by Springer Nature in Environmental Health
- Vol. 16 (1) , 1-7
Open AccessOccupational exposures and determinants of ultrafine particle concentrations during laser hair removal procedures
Occupational exposures to ultrafine particles in the plume generated during laser hair removal procedures, the most commonly performed light based cosmetic procedure, have not been thoroughly characterized. Acute and chronic exposures to ambient ultrafine particles have been associated with a number of negative respiratory and cardiovascular health effects. Thus, the aim of this study was to measure airborne concentrations of particles in a diameter size range of 10 nm to 1 μm in procedure rooms during laser hair removal procedures. TSI Model 3007 Condensation Particle Counters were used to quantify the particle count concentrations in the waiting and procedure rooms of a dermatology office. Particle concentrations were sampled before, during, and after laser hair removal procedures, and characteristics of each procedure were noted by the performing dermatologist. Twelve procedures were sampled over 4 days. Mean ultrafine particle concentrations in the waiting and procedure rooms were 14,957.4 particles/cm3 and 22,916.8 particles/cm3 (p < 0.0001), respectively. Compared to background ultrafine particle concentrations before the procedure, the mean concentration in the procedure room was 2.89 times greater during the procedure (p = 0.009) and 2.09 times greater after the procedure (p = 0.007). Duration of procedure (p = 0.006), body part (p = 0.013), and the use of pre-laser lotion/type of laser (p = 0.039), were the most important predictors of ultrafine particle concentrations. Use of a smoke evacuator (a recommended form of local exhaust ventilation) positioned at 30.5 cm from the source, as opposed to the recommended 1–2 in., lowered particle concentrations, but was not a statistically significant predictor (p = 0.49). Laser hair removal procedures can generate high exposures to ultrafine particles for dermatologists and other individuals performing laser hair removal, with exposure varying based on multiple determinants.
- 20 December 2016
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (1) , 153-162
Cross-Linked Fluorescent Supramolecular Nanoparticles as Finite Tattoo Pigments with Controllable Intradermal Retention Times
Tattooing has been utilized by the medical community for precisely demarcating anatomic landmarks. This practice is especially important for identifying biopsy sites of nonmelanoma skin cancer (NMSC) due to the long interval (i.e., up to 3 months) between the initial diagnostic biopsy and surgical treatment. Commercially available tattoo pigments possess several issues, which include causing poor cosmesis, being mistaken for a melanocytic lesion, requiring additional removal procedures when no longer desired, and potentially inducing inflammatory responses. The ideal tattoo pigment for labeling of skin biopsy sites for NMSC requires (i) invisibility under ambient light, (ii) fluorescence under a selective light source, (iii) a finite intradermal retention time (ca. 3 months), and (iv) biocompatibility. Herein, we introduce cross-linked fluorescent supramolecular nanoparticles (c-FSNPs) as a “finite tattoo” pigment, with optimized photophysical properties and intradermal retention time to achieve successful in vivo finite tattooing. Fluorescent supramolecular nanoparticles encapsulate a fluorescent conjugated polymer, poly[5-methoxy-2-(3-sulfopropoxy)-1,4-phenylenevinylene] (MPS-PPV), into a core via a supramolecular synthetic approach. FSNPs which possess fluorescent properties superior to those of the free MPS-PPV are obtained through a combinatorial screening process. Covalent cross-linking of FSNPs results in micrometer-sized c-FSNPs, which exhibit a size-dependent intradermal retention. The 1456 nm sized c-FSNPs display an ideal intradermal retention time (ca. 3 months) for NMSC lesion labeling, as observed in an in vivo tattoo study. In addition, the c-FSNPs induce undetectable inflammatory responses after tattooing. We believe that the c-FSNPs can serve as a “finite tattoo” pigment to label potential malignant NMSC lesions.
- 20 December 2016
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 11 (1) , 153-162
Cross-Linked Fluorescent Supramolecular Nanoparticles as Finite Tattoo Pigments with Controllable Intradermal Retention Times
Tattooing has been utilized by the medical community for precisely demarcating anatomic landmarks. This practice is especially important for identifying biopsy sites of nonmelanoma skin cancer (NMSC) due to the long interval (i.e., up to 3 months) between the initial diagnostic biopsy and surgical treatment. Commercially available tattoo pigments possess several issues, which include causing poor cosmesis, being mistaken for a melanocytic lesion, requiring additional removal procedures when no longer desired, and potentially inducing inflammatory responses. The ideal tattoo pigment for labeling of skin biopsy sites for NMSC requires (i) invisibility under ambient light, (ii) fluorescence under a selective light source, (iii) a finite intradermal retention time (ca. 3 months), and (iv) biocompatibility. Herein, we introduce cross-linked fluorescent supramolecular nanoparticles (c-FSNPs) as a “finite tattoo” pigment, with optimized photophysical properties and intradermal retention time to achieve successful in vivo finite tattooing. Fluorescent supramolecular nanoparticles encapsulate a fluorescent conjugated polymer, poly[5-methoxy-2-(3-sulfopropoxy)-1,4-phenylenevinylene] (MPS-PPV), into a core via a supramolecular synthetic approach. FSNPs which possess fluorescent properties superior to those of the free MPS-PPV are obtained through a combinatorial screening process. Covalent cross-linking of FSNPs results in micrometer-sized c-FSNPs, which exhibit a size-dependent intradermal retention. The 1456 nm sized c-FSNPs display an ideal intradermal retention time (ca. 3 months) for NMSC lesion labeling, as observed in an in vivo tattoo study. In addition, the c-FSNPs induce undetectable inflammatory responses after tattooing. We believe that the c-FSNPs can serve as a “finite tattoo” pigment to label potential malignant NMSC lesions.
- Open Access
- 1 December 2016
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 152 (12) , 1320-1326
Gaseous and Particulate Content of Laser Hair Removal Plume
Many important surgical procedures involving thermal energy produce an aerosolized byproduct known as surgical plume, which has caused concerns regarding risks associated with long-term exposure.1-4 Investigative reports5 have led to efforts to minimize surgical plume exposure in the work environment. Numerous chemicals have been found in plumes generated by carbon dioxide and Nd:YAG laser tissue ablation, including benzene, formaldehyde, acrolein, carbon monoxide, and hydrogen cyanide.6 Larger organic aerosolized particles, including cellular clumps, erythrocytes, human papillomavirus DNA, bacteriophage, bacteria, and human immunodeficiency virus DNA, have been identified in laser plume.7-12
- 1 December 2016
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 152 (12) , 1320-1326
Open AccessGaseous and Particulate Content of Laser Hair Removal Plume
Many important surgical procedures involving thermal energy produce an aerosolized byproduct known as surgical plume, which has caused concerns regarding risks associated with long-term exposure.1-4 Investigative reports5 have led to efforts to minimize surgical plume exposure in the work environment. Numerous chemicals have been found in plumes generated by carbon dioxide and Nd:YAG laser tissue ablation, including benzene, formaldehyde, acrolein, carbon monoxide, and hydrogen cyanide.6 Larger organic aerosolized particles, including cellular clumps, erythrocytes, human papillomavirus DNA, bacteriophage, bacteria, and human immunodeficiency virus DNA, have been identified in laser plume.7-12
- 1 October 2013
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 39 (10) , 1535-1536
Rapidly Proliferating Apocrine Hidradenoma Treated using Mohs Micrographic Surgery
- 1 October 2013
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 39 (10) , 1535-1536
Rapidly Proliferating Apocrine Hidradenoma Treated using Mohs Micrographic Surgery
- 1 November 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (11) , 1879-1881
Ulceration of Mature Surgical Scars Following Nonablative Fractional Photothermolysis Associated with Intralesional Lidocaine Injections
- 1 November 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (11) , 1879-1881
Ulceration of Mature Surgical Scars Following Nonablative Fractional Photothermolysis Associated with Intralesional Lidocaine Injections
- 1 September 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (9) , 1456-1460
Incidence of Invasive Squamous Cell Carcinomas in Biopsy-Proven Squamous Cell Carcinomas In Situ Sent for Mohs Micrographic Surgery
Squamous cell carcinoma (SCC) in situ (SCCIS) is often treated without any pathologic confirmation of tumor clearance. It is unclear how often an invasive SCC is harbored within a lesion in which the initial biopsy demonstrated SCCIS because of inadequate sampling. This study examines the final histologic diagnosis of cases in which the initial biopsies were diagnosed as SCCIS and evaluates factors that may correlate with a histologic upstaging of the diagnosis. We prospectively recruited 29 consecutive patients with biopsy-proven SCCIS sent for Mohs micrographic surgery (MMS). Each tumor underwent MMS, and the central blocks of the Mohs debulking specimens were horizontally sectioned at 30-μm intervals until exhausted. A fellowship-trained Mohs surgeon and a board-certified dermatopathologist processed and examined these sections to determine the final histologic diagnosis of the tumor. Of the 29 subjects with biopsy-proven SCCIS, nine were found to harbor invasive SCC on final histology. Of the remaining lesions, seven had residual SCCIS, whereas the rest exhibited only actinic keratoses or scars. Approximately 31% of lesions showed evidence of invasive SCC. Correlating the clinical characteristics of the lesions with their corresponding final histologic diagnoses, the lesions harboring invasive SCC were more likely to demonstrate clinical signs of residual tumor (scales and papular changes) and be larger than 1.4 cm in diameter. Our experience at a single institution in the northeastern United States may not be reflective of a wider population. There is also a possible referral bias, because only lesions with high clinical suspicion for invasive SCC were referred for MMS. Although biopsy-proven SCCIS is often treated with modalities that are best suited for superficial disease and do not involve a final pathologic confirmation of clearance (e.g., cryotherapy, electrodesiccation and curettage), this study demonstrated that up to 31% of biopsy-proven SCCIS lesions may harbor invasive SCC. Clinical signs of residual tumor and a diameter larger than 1.4 cm are statistically significant predictors of underlying invasive SCC. These data suggest that treatment modalities that include histologic control of tumor removal should also be strongly considered for the treatment of select biopsy-proven SCCIS meeting the above criteria.
- 1 September 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (9) , 1456-1460
Incidence of Invasive Squamous Cell Carcinomas in Biopsy-Proven Squamous Cell Carcinomas In Situ Sent for Mohs Micrographic Surgery
Squamous cell carcinoma (SCC) in situ (SCCIS) is often treated without any pathologic confirmation of tumor clearance. It is unclear how often an invasive SCC is harbored within a lesion in which the initial biopsy demonstrated SCCIS because of inadequate sampling. This study examines the final histologic diagnosis of cases in which the initial biopsies were diagnosed as SCCIS and evaluates factors that may correlate with a histologic upstaging of the diagnosis. We prospectively recruited 29 consecutive patients with biopsy-proven SCCIS sent for Mohs micrographic surgery (MMS). Each tumor underwent MMS, and the central blocks of the Mohs debulking specimens were horizontally sectioned at 30-μm intervals until exhausted. A fellowship-trained Mohs surgeon and a board-certified dermatopathologist processed and examined these sections to determine the final histologic diagnosis of the tumor. Of the 29 subjects with biopsy-proven SCCIS, nine were found to harbor invasive SCC on final histology. Of the remaining lesions, seven had residual SCCIS, whereas the rest exhibited only actinic keratoses or scars. Approximately 31% of lesions showed evidence of invasive SCC. Correlating the clinical characteristics of the lesions with their corresponding final histologic diagnoses, the lesions harboring invasive SCC were more likely to demonstrate clinical signs of residual tumor (scales and papular changes) and be larger than 1.4 cm in diameter. Our experience at a single institution in the northeastern United States may not be reflective of a wider population. There is also a possible referral bias, because only lesions with high clinical suspicion for invasive SCC were referred for MMS. Although biopsy-proven SCCIS is often treated with modalities that are best suited for superficial disease and do not involve a final pathologic confirmation of clearance (e.g., cryotherapy, electrodesiccation and curettage), this study demonstrated that up to 31% of biopsy-proven SCCIS lesions may harbor invasive SCC. Clinical signs of residual tumor and a diameter larger than 1.4 cm are statistically significant predictors of underlying invasive SCC. These data suggest that treatment modalities that include histologic control of tumor removal should also be strongly considered for the treatment of select biopsy-proven SCCIS meeting the above criteria.
- 1 March 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (3) , 479-483
Ultraviolet-Fluorescent Tattoo Location of Cutaneous Biopsy Site
Cutaneous biopsies often heal with little or no scarring. Prior studies have shown an alarming percentage of patients who incorrectly identify biopsy sites at the time of surgery. To investigate the safety and utility of an ultraviolet (UV)-fluorescent tattoo for biopsy site identification. A preclinical proof of concept was established with skin culture. An UV-fluorescent tattoo was applied to discarded neonatal foreskin in culture medium. The stability of the tattooed skin was examined clinically and histologically. One patient with a recurrent basal cell carcinoma in a difficult-to-identify location underwent tattoo application at the time of biopsy to demarcate the site. The patient was monitored for tattoo reaction and referred for surgical excision. The cultured tissue exhibited stable UV fluorescence with daily washing. Tissue histology demonstrated tattoo particles lining the skin edge under fluorescent microscopy. The patient was reluctant to undergo another surgical procedure and instead returned to our clinic at 3 months and 17 months after the biopsy for management of other tumors. The patient had no symptoms of allergic reaction to the tattoo dye. The fluorescent tattoo remains invisible under visible light and visible only under Wood's light. The present study documents the utility of an UV-fluorescent tattoo to locate a biopsy site.
- 1 March 2012
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 38 (3) , 479-483
Ultraviolet-Fluorescent Tattoo Location of Cutaneous Biopsy Site
Cutaneous biopsies often heal with little or no scarring. Prior studies have shown an alarming percentage of patients who incorrectly identify biopsy sites at the time of surgery. To investigate the safety and utility of an ultraviolet (UV)-fluorescent tattoo for biopsy site identification. A preclinical proof of concept was established with skin culture. An UV-fluorescent tattoo was applied to discarded neonatal foreskin in culture medium. The stability of the tattooed skin was examined clinically and histologically. One patient with a recurrent basal cell carcinoma in a difficult-to-identify location underwent tattoo application at the time of biopsy to demarcate the site. The patient was monitored for tattoo reaction and referred for surgical excision. The cultured tissue exhibited stable UV fluorescence with daily washing. Tissue histology demonstrated tattoo particles lining the skin edge under fluorescent microscopy. The patient was reluctant to undergo another surgical procedure and instead returned to our clinic at 3 months and 17 months after the biopsy for management of other tumors. The patient had no symptoms of allergic reaction to the tattoo dye. The fluorescent tattoo remains invisible under visible light and visible only under Wood's light. The present study documents the utility of an UV-fluorescent tattoo to locate a biopsy site.
- 1 March 2011
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 37 (3) , 311-319
Preoperative Expectations and Values of Patients Undergoing Mohs Micrographic Surgery
- 1 March 2011
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 37 (3) , 311-319
Preoperative Expectations and Values of Patients Undergoing Mohs Micrographic Surgery